Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zai Lab Ltd (ZLAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8119
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It develops drugs for treatment of ovarian cancer and breast cancer in Phase II stage, lung cancer in Phase II stage, infectious diseases in phase III stage, and eczema and psoriasis in phase II stage, among others. Zai Lab’s FPA144 is used for the treatment of gastric cancer and EXT2514SUL is used for acinetobacter baumannii. The company operates its offices in Pudong, Beijing and Suzhou, China. Zai Lab is headquartered in Pudong, China.

Zai Lab Ltd (ZLAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zai Lab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ZAI Lab Raises USD30 Million in Series C Financing 12
dMed Raises USD8 Million in Series A Financing 13
ZAI Labs Raises More Than USD100 Million in Series B Financing 14
ZAI Labs Raises More Than USD30 Million in Series A Venture Financing 15
Partnerships 17
Zai Lab Enters into Licensing Agreement with Paratek Pharma 17
GE Healthcare and Zai Lab Enter into Agreement 18
Zai Lab (Shanghai) Enters into Partnership with Tsinghua University Immunology Institute 19
Licensing Agreements 20
Zai Lab Enters into Licensing Agreement with Novocure 20
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 22
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Zai Lab Enters into Licensing agreement with GlaxoSmithKline 25
Zai Lab Enters into Licensing Agreement with Tesaro 26
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 27
Zai Lab Enters into Licensing Agreement with UCB 28
Zai Lab Enters into Licensing Agreement with Sanofi 29
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 30
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 31
Equity Offering 32
Zai Lab Prices Public Offering of ADS for USD150 Million 32
Zai Lab Raises USD172.5 Million in IPO 34
Zai Lab Ltd – Key Competitors 36
Zai Lab Ltd – Key Employees 37
Zai Lab Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Corporate Communications 39
Aug 14, 2018: Zai Lab names professor Kai-Xian Chen, Ph.D., as Board Director 39
Jun 05, 2018: Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Zai Lab Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zai Lab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zai Lab Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ZAI Lab Raises USD30 Million in Series C Financing 12
dMed Raises USD8 Million in Series A Financing 13
ZAI Labs Raises More Than USD100 Million in Series B Financing 14
ZAI Labs Raises More Than USD30 Million in Series A Venture Financing 15
Zai Lab Enters into Licensing Agreement with Paratek Pharma 17
GE Healthcare and Zai Lab Enter into Agreement 18
Zai Lab (Shanghai) Enters into Partnership with Tsinghua University Immunology Institute 19
Zai Lab Enters into Licensing Agreement with Novocure 20
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 22
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Zai Lab Enters into Licensing agreement with GlaxoSmithKline 25
Zai Lab Enters into Licensing Agreement with Tesaro 26
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 27
Zai Lab Enters into Licensing Agreement with UCB 28
Zai Lab Enters into Licensing Agreement with Sanofi 29
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 30
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 31
Zai Lab Prices Public Offering of ADS for USD150 Million 32
Zai Lab Raises USD172.5 Million in IPO 34
Zai Lab Ltd, Key Competitors 36
Zai Lab Ltd, Key Employees 37
Zai Lab Ltd, Other Locations 38

List of Figures
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kazia Therapeutics Ltd (KZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (A …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • ShotSpotter Inc (SSTI):企業の財務・戦略的SWOT分析
    ShotSpotter Inc (SSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • E.ON SE:発電所・企業SWOT分析
    E.ON SE - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives …
  • SOSINA Exploration Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Sosina Exploration Ltd (Sosina), formerly Odegaard UK Ltd is an oil and gas company that offers exploration and development services. The company identifies probable oil and gas accumulations in co-operation with partners within the oil and gas industries. It provides services in geological …
  • NetScout Systems, Inc. (NTCT):企業の財務・戦略的SWOT分析
    NetScout Systems, Inc. (NTCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhib …
  • iRobot Corp (IRBT):企業の財務・戦略的SWOT分析
    iRobot Corp (IRBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Vyriad Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Vyriad Inc (Vyriad), formerly Omnis Pharma Inc is a clinical stage bio-pharmaceutical company that develops viral-based novel oncolytic therapies for the treatment of cancer. The company’s pipeline products include various engineered viruses in phase 1 for the treatment of non small cell lun …
  • Public Bank Berhad:戦略・SWOT・企業財務分析
    Public Bank Berhad - Strategy, SWOT and Corporate Finance Report Summary Public Bank Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Celsius Holdings, Inc.:企業の戦略・SWOT・財務情報
    Celsius Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Celsius Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CHS Inc (CHSCP):企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Khatam al-Anbia:企業の戦略的SWOT分析
    Khatam al-Anbia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Nachi-Fujikoshi Corp (6474):企業の財務・戦略的SWOT分析
    Nachi-Fujikoshi Corp (6474) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Fri-El Green Power SpA-エネルギー分野:企業M&A・提携分析
    Summary Fri-El Green Power SpA (Fri-El) is a renewable energy company that offers production of electric energy from renewable sources. The company develops, builds and manages power stations fuelled with biogas. Its wind energy is produced through wind turbine generators that convert wind to kineti …
  • Avery Dennison Corporation (AVY)-医療機器分野:企業M&A・提携分析
    Summary Avery Dennison Corporation (Avery Dennison) is a labeling and packaging materials and solutions provider. The company produces pressure-sensitive materials, tags, labels, tickets, and other converted products. It also manufactures and sells fasteners, tickets, tags, radio-frequency identific …
  • Polenergia SA (PEP):企業の財務・戦略的SWOT分析
    Polenergia SA (PEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • PRA Health Sciences Inc (PRAH)-製薬・医療分野:企業M&A・提携分析
    Summary PRA Health Sciences Inc (PRA) is a contract research organization(CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometric …
  • Mitsui Mining & Smelting Co Ltd:企業の戦略・SWOT・財務分析
    Mitsui Mining & Smelting Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mitsui Mining & Smelting Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Pharmstandard:企業の戦略的SWOT分析
    Pharmstandard - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆